Eight domains of the peptide landscape.

GLP-1 and dual-agonist chemistry. By a wide margin the best-evidenced group here — it holds most of the approved products on the site and the largest trial populations, and it is the only category where the main question is which compound rather than whether any of them have been studied.

FDA-approved

9

Have human studies

15

No human studies

4

Of 19: 15 studied, 4 not. 9 of the studied have an approved product.

BPC-157, TB-500, GHK-Cu and the IGF-1 variants. The sharpest gap on the site between attention and evidence: these are among the most-read compounds we track and among the least-tested in humans. Not one has an FDA-approved product.

FDA-approved

0

Have human studies

4

No human studies

4

Of 8: 4 studied, 4 not. 0 of the studied have an approved product.

GHRH and GHRP analogues — the compounds that prompt the body to release its own growth hormone rather than supplying it. A split group: a couple carry approved products and real trial records, and the rest are known mainly from the clinic and gym market.

FDA-approved

2

Have human studies

4

No human studies

4

Of 8: 4 studied, 4 not. 2 of the studied have an approved product.

Bioregulators, mitochondrial peptides and NAD+ chemistry. Mixed and easy to misread — some members are long-established molecules with enormous general literature, which is not the same as evidence for the longevity use they are sold for.

FDA-approved

1

Have human studies

3

No human studies

3

Of 6: 3 studied, 3 not. 1 of the studied have an approved product.

Largely Russian-origin nootropic chemistry, plus sleep and anxiolytic peptides. The thinnest registry record of any category on the site: almost nothing here has a registered human trial in English-language registries, which is a fact about the public record rather than proof of absence.

FDA-approved

0

Have human studies

1

No human studies

6

Of 7: 1 studied, 6 not. 0 of the studied have an approved product.

Melanocortin and GnRH chemistry acting centrally rather than locally. Small but unusually well-documented for its size — most members have registered human studies and several have approved products.

FDA-approved

3

Have human studies

5

No human studies

0

Of 5: 5 studied, 0 not. 3 of the studied have an approved product.

Copper peptides, melanocortin tanning agents and cosmetic sequences. Most are regulated as cosmetics rather than as drugs, which is why the trial record is thin: a cosmetic ingredient never has to run the trials a drug does.

FDA-approved

1

Have human studies

5

No human studies

2

Of 7: 5 studied, 2 not. 1 of the studied have an approved product.

Thymic peptides and anti-inflammatory fragments. A small group with a partial trial record and no FDA-approved product.

FDA-approved

0

Have human studies

3

No human studies

2

Of 5: 3 studied, 2 not. 0 of the studied have an approved product.

Approved peptide medicines for bone density and intestinal conditions. Grouped by indication rather than chemistry because they share nothing else — and included because they are among the best-evidenced peptides in existence, which the consumer categories above would otherwise have hidden.

FDA-approved

3

Have human studies

3

No human studies

0

Of 3: 3 studied, 0 not. 3 of the studied have an approved product.